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A growing number of drugs have been shown to prolong cardiac repolarization, predisposing 
individuals to life-threatening ventricular arrhythmias known as Torsades de Pointes. Most of these 
drugs are known to interfere with the human ether à-gogo related gene 1 (hERG1) channel, whose 
current is one of the main determinants of action potential duration. Prolonged repolarization 
is reflected by lengthening of the QT interval of the electrocardiogram, as seen in the suitably 
named drug-induced long QT syndrome. Chirality (presence of an asymmetric atom) is a common 
feature of marketed drugs, which can therefore exist in at least two enantiomers with distinct 
three-dimensional structures and possibly distinct biological fates. Both the pharmacokinetic 
and pharmacodynamic properties can differ between enantiomers, as well as also between 
individuals who take the drug due to metabolic polymorphisms. Despite the large number of 
reports about drugs reducing the hERG1 current, potential stereoselective contributions have 
only been scarcely investigated. In this review, we present a non-exhaustive list of clinically 
important molecules which display chiral toxicity that may be related to hERG1-blocking 
properties. We particularly focus on methadone cardiotoxicity, which illustrates the importance 
of the stereoselective effect of drug chirality as well as individual variations resulting from 
pharmacogenetics. Furthermore, it seems likely that, during drug development, consideration 
of chirality in lead optimization and systematic assessment of the hERG1 current block with all 
enantiomers could contribute to the reduction of the risk of drug-induced LQTS.
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arrhythmias that can cause fainting and/or sudden death, named 
Torsades de Pointes (TdP) (Figure 2). Such genetic disorders are 
referred to as congenital long QT syndromes (LQTS). Another 
hERG1-related LQTS has been shown to be drug-induced (Abriel 
et al., 2004). A variety of medications have the undesired ability to 
trigger life-threatening arrhythmias and sudden cardiac death due 
to their inhibition of the hERG1 channel. This adverse effect raises 
important concern in the pharmaceutical area (Brown, 2004). Since 
structures and therapeutic classes involved are so diverse, hERG1 
liability must be assessed for all new drugs, sometimes leading to 
considerable economic loss if, after years of development, the drug 
reveals to block this potassium channel.
Recently, stereoselectivity in both pharmacokinetics (PK) and 
pharmacodynamics (PD) disclosed the chiral toxicity of metha-
done on the hERG1 channel (Eap et al., 2007). The main goal of 
this review is to summarize the most relevant literature regarding 
potential stereoselective inhibition of the cardiac hERG1 channel 
and to discuss the advantages of focusing on single enantiomers for 
the development of drugs devoid of hERG1-blocking properties.
Drug block of the herg1 channel
The first described case of drug-induced LQTS was attributable to 
quinidine, an antiarrhythmic class Ia drug intended to act on Na+ 
channels (Roden et al., 1986). Syncopal episodes following initiation 
of quinidine therapy were recognized shortly after the introduc-
tion of the drug in the 1920s, well before the description of LQTS 
and the understanding of the molecular mechanisms (reviewed 
in Roden, 2006). Later in the development of antiarrhythmic 
IntroDuctIon
In cardiac cells, the action potential (AP) is elicited by the orches-
trated activity of several types of ion channels. Among them, the 
voltage-gated potassium channel is crucial for normal human car-
diac electrical activity. The human ether à-gogo related gene (hERG1) 
channel, responsible for the rapid component of the delayed rec-
tifier potassium current (I
Kr
), is one of the main determinants of 
action potential duration (APD). Functional hERG1 channels are 
formed by the assembly of four α-subunits encoded by the KCNH2 
gene. Each α-subunit of hERG1 consists of six transmembrane 
domains (S1–S6) and intracellular amino- and carboxy-termini. 
The voltage sensor resides in the first four transmembrane domains, 
while the S5 and S6 helices, the selectivity filter, and the pore-helix 
compose the pore-forming units (Figure 1).
Many loss-of-function mutations in the KCNH2 gene can pro-
long APD, reflected by an increase of the QT interval on the elec-
trocardiogram (ECG), due to the reduction of repolarizing currents 
as presented in Figure 2. Lengthening of the QT interval when 
corrected to the heart rate (QTc) is a well-known risk factor for 
Abbreviations: AP, action potential; APD, action potential duration; DAAM, levo-
α-acetylmethadol; EM, extensive metabolizer; ECG, electrocardiogram; HEK293 
cells, human embryonic kidney 293 cells; hERG1, human ether-à-gogo related gene 
1; IC
50
, half-maximal inhibitory concentration; I
hERG1
, rapid component of the de-
layed; I
Kr
, rapid component of the delayed rectifier potassium current; K
v
 channels, 
voltage-gated potassium channels; LAAM, levo-α-acetylmethadol; LQTS, long QT 
syndrome; MMT, methadone maintenance treatment; Na
v
 channels, voltage-gated 
sodium channels; PK, pharmacokinetics; PD, pharmacodynamics; SM, slow me-
tabolizer.
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severely restricted because of this rare and potentially fatal toxicity. 
Although not an exhaustive list of hERG1 channel blockers, some 
examples include the antimuscarinic drug terodiline (withdrawal in 
1991), the antianginal agent mibefradil (1998), the anti-histaminics 
terfenadine and astemizole (withdrawal in 1998 and 1999, respec-
tively), the antibiotic grepafloxacin (1999), the gastrointestinal 
prokinetic cisapride (2000), the analgesic levo-α-acetylmethadol 
(2003), and the neuroleptics sertindole (since 1998) and thiori-
dazine (2005). A growing number of non-class III antiarrhythmic 
agents have been shown to prolong cardiac repolarization, pre-
disposing an individual to sudden cardiac death. Drugs proven to 
lengthen the QT interval and/or drugs associated with TdP were 
estimated to comprise ∼2–3% of all drug prescriptions (De Ponti 
et al., 2000). Many of these drugs remain on the market1 because 
their benefits are still considered to outweigh their risks. Regulatory 
authorities now demand systematic assessment of the torsadogenic 
risk (ICH S7B, 2005) of any newly developed drug.
therapy, molecules were specifically designed to block K+ currents 
(class III antiarrhythmic agents), such as dofetilide and ibutilide. 
Unfortunately, such drugs predictably prolong the QTc interval, 
resulting in potentially lethal ventricular arrhythmias in 5–7% of 
recipients (Marban, 2002). These drugs, along with other molecules 
of the methanesulfonanilide group, have been shown to block the 
hERG1 channel (Spector et al., 1996; Yang et al., 1997). It is now 
recognized that many structurally unrelated drugs, designed to act 
on non-cardiac targets, unintentionally block the repolarizing cur-
rent I
Kr
. Although disruption of hERG1 protein trafficking has also 
been reported, blockage of the hERG1 current or I
hERG1
 accounts for 
more than 95% of drug-induced delayed repolarization.
In the past 15 years, the most common reason for withdrawal 
or restriction of marketed drugs has been the prolongation of the 
QT interval associated with polymorphic ventricular tachycardia 
or TdP (Roden, 2004). The rare incidence of these life-threatening 
arrhythmias explains why they are not readily observed during 
clinical trials or post-marketing surveillance. Many drugs have been 
removed from the market after years of use or had their availability 
FiGuRE 1 | The hERG1 channel structure and putative binding region for 
blocking drugs. (A) Schematized hERG1 tetrameric channel at the plasma 
membrane and (B) pore-forming region in schematic and (C) ribbon 
representation. The pale circles locate the general drug binding site in the cavity 
created by the pore-forming domain, i.e., transmembrane domains (S5, S6), 
pore-helix (P-h) and selectivity filter (Sel. Filter) of the four α-subunits. For clarity, 
only three subunits are depicted. (D) Magnification of one α-subunit with six 
transmembrane domains (S1-S6), S5-P linker or turret loop, pore-helix (P-helix) and 
selectivity filter (SF). Both N- and C-termini are intracellular with respectively 
identified Per-Arnt-Sim (PAS) domain and cyclic nucelotide binding domain (cNBD).
1see www.QTdrugs.org
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sensitive to MK-499 inhibition (Mitcheson et al., 2000a). Similar 
reductions in block potency were obtained with Y652A and F656A 
mutants for terfenadine and cisapride, as well as many other com-
pounds as reviewed in Stansfeld et al. (2007). Mitcheson’s group 
provided further evidence to the intra-cavity block of the hERG1 
channel by rather large molecules, such as methanesulfonanilide 
drugs. Using the hERG1-D540K mutant that has the unusual prop-
erty of opening in response to hyperpolarization, they confirmed 
that MK-499 blocked the hERG1 channel in the inner vestibule, as 
MK-499 was trapped by closure of the activation gate (Mitcheson 
et al., 2000b). The ability of HERG1 (wild-type and D540K) chan-
nels to trap MK-499 suggests that its vestibule is larger than other 
well studied K
v
1 (Shaker family) channels. Unlike other voltage-
gated K+ channels (e.g., K
v
1–K
v
4), hERG1 lacks the Pro-x-Pro (x for 
any amino acid) sequence in the S6 domain, which is thought to be 
responsible for the sharp bend in the S6 helices, thereby reducing 
the volume of the channel cavity (Mitcheson et al., 2000a; Labro 
et al., 2003). Altogether, these results show that the residues lin-
ing the pore (especially Tyr652 and Phe656) are major structural 
determinants for hERG1 current block.
chIral Drugs anD stereoselectIvIty
A chiral molecule – from the Greek word χείρ for hand – is one 
whose structure lacks an internal plane of symmetry and has a 
non-superimposable mirror image (Figure 3). Although chiral 
molecules share the same molecular formula, molecular weight, 
atom-to-atom linkages, and bonding distances, their three-dimen-
sional arrangements differ. Chirality most often results from the 
presence of an asymmetrical atom, usually a carbon atom with 
four different substituents. A chiral molecule and its mirror image 
are called enantiomers, and different methods are used to distin-
guish them. Chiral nomenclature can either describe how each 
Molecular DeterMInants of the herg1 channel block
Their are a wide variety of drugs of different classes and structures 
that can inhibit the hERG1 channel. The first insights into the 
reasons for this widespread block came about a decade ago. Based 
upon the assumption that the block of hERG1 occurred in the cav-
ity of the channel (Figure 1), similar to the Na+ and Ca2+ channels, 
Mitcheson et al. (2000a) used alanine-scanning mutagenesis of the 
hERG1 pore-helix and S6 domain to determine the binding sites for 
MK-499, a potent methanesulfonanilide blocker of the K+ channel. 
Channels with alanine mutations in the S6 domain (G648A, Y652A, 
and F656A) were minimally inhibited by MK-499 as compared to 
wild-type channels (Mitcheson et al., 2000a). Based on a homol-
ogy model of the hERG1 channel, these aromatic residues were 
predicted to line the pore cavity. In addition, three channels with a 
mutation located in the base of the pore-helix (T623A, S624A, and 
V625A) and one located in the S6 domain (V659A) were also less 
FiGuRE 2 | Ventricular action potentials and related ECG signals: 
prolonged QT interval is a risk factor for Torsades de Pointes. (A) Normal 
and prolonged ventricular action potential due to (B) reduction of hERG1 
currents in LQTS are reflected (C) on the ECG recording with lengthening of 
the QT interval. (D) Schematized ECG recording presenting the onset of 
Torsades de Pointes in a patient with long QT syndrome.
FiGuRE 3 | A chiral molecule and its different names: the amino acid 
alanine. The left-handed molecule (L-alanine or (S)-alanine) is presented with 
its mirror image, the right-handed molecule (d-alanine or (R)-alanine). Note that 
the optical activity (dextro- or levorotatory) cannot be deduced from the 
structure.
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these patients may be more likely to have high plasma concentra-
tions of perhexiline with a consequent increased susceptibility to 
adverse effects (Walker et al., 1999). Some drugs are able to convert 
extensive metabolizers into slow metabolizers by interfering with 
the cytochrome pathway, and may cause drug–drug interactions. 
The gastrointestinal prokinetic agent cisapride is a good example 
of a high-affinity blocker of the hERG1 channel being substrate 
of the CYP3A4. Prolongation of the QT interval along with severe 
cardiac outcomes have been reported after concomitant adminis-
tration of cisapride with macrolide antibiotics, such as erythro-
mycin (Tierney et al., 1997), or with azole antifungal agents like 
ketoconazole (Michalets and Williams, 2000). These drugs alone 
may prolong the QT interval by blocking I
hERG1
, but they are mainly 
responsible for the drastic increase in the plasma concentration of 
cisapride due to CYP3A4 inhibition.
Drug-metabolizing enzymes are constituted of chiral entities, 
thus their tertiary structure creates unique three-dimensional bind-
ing and/or catalytic domains that enable the identification of one 
enantiomer from another (Smith, 2009). Stereoselective metabolism 
has long been recognized as a source of variable disposition between 
enantiomers. Fluoxetine is an antidepressant of the selective sero-
tonin reuptake inhibitor class (Figure 4). In a study by Margolis 
et al. (2000), N-demethylation of this molecule was assessed by 
heterogeneously expressed human cytochrome P450 enzymes. 
Their results suggested that CYP2D6, CYP2C9, and CYP3A4 greatly 
contribute to the hepatic metabolism of this chiral antidepressant 
drug. In a contemporaneous study, stereoselective biotransforma-
tion of racemic fluoxetine was assessed in CYP2D6 sparteine slow 
and extensive metabolizers (Fjordside et al., 1999). In SMs, both 
oral clearance (3 versus 17 L/h) and half-life (9.5 versus 6.1 days) 
revealed a significantly slower metabolism of (R)-fluoxetine com-
pared to the (S)-form, respectively; while no difference between 
enantiomers was observed in EMs (oral clearance: 36 and 40 L/h, 
half-life: 2.1 and 1.1 days). Because (R)-fluoxetine has a shorter 
half-life – it yields an inactive metabolite, whereas (S)-norfluoxetine 
is as active as (R)- or (S)-fluoxetine in selective serotonin reuptake 
inhibition – the clinical availability of this enantiomer could prove 
beneficial in elderly individuals. Results from early clinical trials, 
however, raised concerns over its potential to prolong the QTc inter-
val at the highest doses administered. This unexpected finding led 
to the termination of the clinical development of this enantiomer 
(reviewed in Shah, 2002). Interestingly, fluoxetine and its major 
metabolite norfluoxetine, have been shown to inhibit the hERG1 
current in vitro (Thomas et al., 2002; Rajamani et al., 2006), and the 
estimated IC
50s
 of direct hERG1 current inhibition in mammalian 
cells are in the range of plasma concentrations reached in humans 
(reviewed in Thomas et al., 2002). Unfortunately, none of these 
studies assessed a potential stereoselective effect of fluoxetine enan-
tiomers. It remains unknown whether the CYP2D6 SM status and 
consequent reduced biotransformation of (R)-fluoxetine played a 
role in the significantly longer QTc intervals measured in the clinical 
trial. Nevertheless, since this antidepressant is widely prescribed and 
the frequency of the sparteine SM phenotype ranges from 2.3 to 
9% according to populations (Eichelbaum et al., 1986; Niewinski 
et al., 2002), it would be instructive to know if this metabolic condi-
tion is an additional risk factor for polymorphic arrhythmias for 
individuals taking fluoxetine.
 enantiomer affects the rotation of polarized light or its absolute 
chemical configuration, as presented in Figure 3. An equimolar 
mixture of a pair of enantiomers is known as racemate and does 
not have any optical activity (reviewed in Smith, 2009). When a 
compound has multiple chiral centers, two molecules that are not 
perfect mirror images of each other are named diastereomers.
Except for their ability to rotate polarized light in opposite direc-
tions, enantiomers have identical chemical and physical properties. 
However, in the presence of other chiral molecules or environments, 
one enantiomer can behave differently from another. The enantiom-
ers of a compound may taste and smell differently, or they may exert 
different activities when used as therapeutics. These effects reflect 
the chirality inherent in biological systems, as the main “building 
blocks” of life (i.e., amino acids and sugars) are chiral. Chirality can 
introduce marked selectivity, and often specificity, in drug action 
(Tucker, 2000). Consequently, stereoselectivity is the preferential 
interaction of one enantiomer molecule with a biological target. 
Since many commonly used drugs are racemates, differentiation 
of the relative contribution of each enantiomer to the overall drug 
action, including stereoselective PK and PD, is essential. While one 
enantiomer is likely responsible for the activity of interest, its paired 
enantiomer could be partially or equally active, inactive or may have 
an antagonist effect. One enantiomer may also have a separate activ-
ity that could be desirable or not (Caner et al., 2004).
PharMacogenetIcs anD stereoselectIve MetabolIsM
A number of genetic variants, either “silent” mutations or poly-
morphisms, have been found to be associated with an increased 
vulnerability for drug-induced LQTS (e.g., Yang et al., 2002; 
Paavonen et al., 2003; Paulussen et al., 2004; Sun et al., 2004). There 
is also evidence that differences in the pharmacokinetic proper-
ties of drugs may be risk factors for drug-induced QT interval 
prolongation. Pharmacogenetic studies assess the genetic causes 
of inter-individual differences in drug response. It is well known 
that genetic variability of drug metabolism can result in functional 
polymorphisms of metabolizing enzyme genes, and among them 
cytochromes P450 (CYP) isoenzymes – essential for the catalysis 
of oxidation of endogenous molecules or xenobiotics during phase 
I – have been extensively studied. Many different human CYP genes 
exist, the most important being CYP2C9, CYP2D6, and CYP3D4, 
since their gene products account for 60–70% of the phase I metab-
olism of clinically important drugs (Ingelman-Sundberg, 2001). 
Mutations in the CYP genes can generate enzymes with abolished, 
reduced, altered, or increased activity. The phenotype of a CYP 
enzyme can be tested by administering a specific substrate, e.g., 
debrisoquine for CYP2D6, and measuring the metabolite-to-parent 
drug ratio in the urine. Individuals with a low ratio have reduced 
enzyme activity and are termed slow metabolizers (SMs) in order to 
differentiate them from extensive metabolizers (EMs). Perhexiline 
and thioridazine are examples of drugs that depend on CYP2D6 
activity and both act on the hERG1 channel (reviewed in Roden 
and Viswanathan, 2005). Walker et al. (1999) studied the block of 
I
hERG1
 by perhexiline, an antianginal agent known to cause QT inter-
val prolongation and TdP. Interestingly, half-maximal inhibitory 
concentrations (IC
50
) were above the clinical plasma concentra-
tions usually observed. Nevertheless, since 8–10% of Caucasians 
and Black individuals are CYP2D6 SMs, the authors proposed that 
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Bupivacaine (Figure 4), a local anesthetic drug belonging to 
the amino amide group, also displays stereoselective effects on its 
main targets, the voltage-gated sodium channels (Na
v
). Although 
some studies demonstrated that the potency and duration of local 
anesthesia in vivo were the same for (S)- and (R)-bupivacaine (Kanai 
et al., 1999), in vitro observations indicated that the (R)-enantiomer 
more potently blocks neuronal sodium channels (Lee-Son et al., 
1992). Accidental intravascular injection or the use of high con-
centrations of local anesthetics can produce profound systemic 
effects, especially in the central nervous and cardiovascular systems. 
Valenzuela and co-workers studied the potential block of cardiac 
channels and the putative differences between enantiomers. Both 
cardiac Na
v
1.5 and K
v
1.5 were inhibited by bupivacaine, with the 
(R)-form being in both cases a more potent blocker (Valenzuela 
et al., 1995a,b). Altogether, these results spoke in favor of the use 
of (S)-bupivacaine, commonly known as levobupivacaine, for an 
increased cardiovascular safety.
stereoselectIve effects on carDIac rePolarIzatIon
Although many reports of drugs blocking the hERG1 current 
are found in the literature (e.g., Snyders et al., 1991; Roy et al., 
1996; Snyders and Chaudhary, 1996; Mohammad et al., 1997; 
Monserrat and Bianchini, 2001; Zhang et al., 2001; Thomas et al., 
2003; Perry et al., 2004), the potential stereoselective contribution 
of the distinct enantiomers has only been scarcely investigated. 
Among the few publications existing, it is worth mentioning the 
work of Yang et al. (2000) in which enantiomers of chromanol 
293B showed no differences on the hERG1 current, but dem-
onstrated a seven-fold stereoselectivity on the KCNQ1/KCNE1 
current block. Likewise, verapamil enantiomers that blocked the 
L-type Ca2+ channels also blocked the K+ hERG1 channels, but 
they had equal potencies of inhibition when tested in Xenopus 
oocytes (Waldegger et al., 1999). The first demonstration of the 
stereoselective block of hERG1 was by Gonzalez et al. (2002). 
The authors, using a heterologous expression system, revealed 
that (S)-bupivacaine was more potent at blocking the I
hERG1
 than 
(R)-bupivacaine, which is remarkably the inverse stereoselectivity 
to that observed in other cardiac channels (Gonzalez et al., 2002). 
The same observation was made for ropivacaine, a structurally 
related anesthetic differing only in the size of the N-substituent 
(Siebrands et al., 2005).
Another historical example is quinidine and its dextrorota-
tory diastereomer quinine (Figure 4). As previously mentioned, 
quinidine has been mainly used as a class I antiarrhythmic drug, 
even though both diastereomers can block the cardiac Na
v
1.5 
(reviewed in White, 2007). Despite quinidine has a greater anti-
plasmodium activity, quinine is still preferentially used to treat 
malaria, because, in contrast to quinidine, no significant cardio-
toxicity has been reported in large prospective studies of quinine 
in uncomplicated and severe malaria (reviewed in White, 2007). 
In a study by Sanchez-Chapula et al. (2003), both diastereomers 
where tested for their ability to block hERG1 channels expressed in 
Xenopus oocytes. Results showed a ∼12-fold difference in the IC
50
 
of block and mutagenesis experiments also unveiled the intracel-
lular and open-state block of the channel by the two diastereom-
ers. In addition to the stereoselective effect on the K+ channel, 
pharmacokinetic differences were observed (in terminal half-life, 
Halofantrine is an antimalarial drug effective for the treatment 
of uncomplicated chloroquine-resistant Plasmodium falciparum. 
Regrettably, this drug has been associated with QT interval prolon-
gation and arrhythmias in patients without any known underlying 
cardiac abnormalities (Mbai et al., 2002). Halofantrine enantiom-
ers (Figure 4) extensively accumulate upon daily administration 
and have high intersubject PK variability. In the clinical study of 
Abernethy et al. (2001), the steady-state plasma concentration of 
(R)-halofantrine exceeded the concentration of (S)-halofantrine 
by approximately two-fold. The correlation between the plasma 
concentration and QT interval appeared to be stronger for the 
(R)- versus the (S)-halofantrine in all but one patient, which 
may be consistent with the increased cardiotoxic potential of the 
(R)-isomer (Abernethy et al., 2001). Abernethy et al. (2001) did, 
however, observe a high variability in the plasma concentrations of 
halofantrine and QTc intervals, but they did not search for any eth-
nical correlations (38% Caucasians versus 62% African-Americans) 
in their cohort of essentially young males. Inter-ethnical variations 
in genes involved in the biotransformation of halofantrine into 
its metabolite may, in part, account for these variations. In addi-
tion to the PK difference, halofantrine produced a stereoselective 
block of the delayed rectifier potassium current in isolated feline 
myocytes, with the (R)-enantiomer being more potent (Wesche 
et al., 2000). Mbai et al. (2002) confirmed that halofantrine and 
its major liver metabolite block the hERG1 channel (IC
50
s at the 
nM range), but the authors did not separately assess the enanti-
omers. Again, further investigation of the pharmacokinetics and 
cardiac toxicity of each chiral entity would be valuable to ensure 
safer drug treatment.
stereoselectIvIty anD Ion channels
Membrane receptors, such as β-adrenergic receptors, often dis-
play marked stereoselectivity in drug pharmacodynamics, in 
either agonist or antagonist activity (Popp et al., 2004). Different 
stereoselective blockers have also been identified for ion channels. 
The levorotatory chromanol 293B was demonstrated to be nearly 
seven-fold more potent than its dextro-form in the block of the 
cardiac KCNQ1/KCNE1 current (Yang et al., 2000). Verapamil was 
the first L-type calcium channel blocker available for the treatment 
of angina pectoris, hypertension and supraventricular arrhythmias 
(Sandler et al., 1968), and its racemic mixture is still widely used 
in the management of these conditions. Although the two enan-
tiomers of verapamil possess similar spectra of pharmacological 
effects, they differ in their pharmacokinetic and pharmacodynamic 
properties. (S)-verapamil is more potent than the (R)-form in 
the block of the L-type Ca2+ current, but it is also preferentially 
metabolized during hepatic first-passage and has a greater vol-
ume of distribution (Busse et al., 2006). Dihydropyridine mol-
ecules, another class of calcium channel modulators, also present 
marked stereoselectivity. Whereas the enantiomer (S)-Bay K 8644 
is a potent activator of L-type Ca2+ channels, the (R)-Bay K 8644 
acts as an antagonist (Triggle, 1996). Moreover, the stereoselective 
effect may be state-dependent, which is a feature unique to ion 
channels. This phenomenon is clearly seen with (S)-Bay K 8644, 
which has activating properties at polarized membrane potentials 
and antagonistic properties at depolarized potentials (reviewed 
in Triggle, 1996).
Frontiers in Pharmacology | Ion Channel and Channelopathies  November 2010 | Volume 1 | Article 137 | 6
Grilo et al. hERG1 and stereoselectivity
pharmacodynamic effects, associated with different therapeu-
tic concentrations, determined the clinical indications of these 
two stereoisomers.
Other enantiomers have been reported to prolong AP or QT 
interval durations, although to the best of our knowledge, the stere-
oselective involvement of hERG1 channel block has not yet been 
demonstrated. Jurkiewicz et al. (1996) studied the effects of the 
class III antiarrhythmic agent RP58866 and its (S)-enantiomer, 
terikalant (Figure 4), on outward K+ currents in guinea pig ven-
tricular myocytes. RP58866 and terikalant potently blocked the I
Kr
, 
volume of distribution at steady-state and plasma protein bind-
ing) resulting in plasma concentrations of unbound quinidine 
being twice that of quinine in a series of subjects receiving the 
drug intravenously (Karbwang et al., 1993). In the same study by 
Karbwang et al. (1993), although both alkaloids prolonged the QTc 
interval compared to baseline, the maximum change after quinine 
infusion was approximately half that after quinidine. According 
to +White’s review (2007), the large difference in hERG1 chan-
nel inhibition may explain why quinine has very little effect on 
ventricular repolarization in vivo. In this case, the stereoselective 
FiGuRE 4 | Chemical structures of selected chiral compounds blocking the hERG1 channel.
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 sufficient to account for the differences in ECGs. Hartigan-Go et al. 
(1996) concluded that QT prolongation with the racemic terodiline 
administration was exclusively imputable to the (R)-enantiomer. 
Later, racemic terodiline was demonstrated to block I
Kr
 and I
hERG1
 at 
clinically relevant concentrations (Jones et al., 1998; Martin et al., 
2006). To our knowledge, no publication has addressed the stere-
oselective effect of terodiline on hERG1.
Propafenone (Figure 4) is another class I antiarrhythmic drug, 
delivered as a racemate, that deserves to be mentioned. In rare 
clinical cases, propafenone has been associated with QT interval 
prolongation and TdP (e.g., Rosengarten and Brooks, 1987; Hii 
et al., 1991). In the early 2000s, racemic propafenone was demon-
strated to block overexpressed hERG1 channels in cellular models 
(Mergenthaler et al., 2001; Paul et al., 2002; Witchel et al., 2004) and 
native I
Kr
 current from isolated rabbit ventricular myocytes (Cahill 
and Gross, 2004) at IC
50
 values comparable with those of quinidine 
0.4–0.8 μM in mammals) and within therapeutic plasma concen-
trations. Both enantiomers have comparable depressant effects on 
Na+ current (QRS widening) in dog Purkinje fibers (Kroemer et al., 
1989), but, in contrast, only (S)-propafenone exerts a β-blocker 
activity (Kroemer et al., 1989). A possible stereoselective interac-
tion with the hERG1 channel remains to be evaluated. Interestingly, 
Kroemer and co-workers evidenced the stereoselective disposition 
of propafenone in humans. In a small study population patients 
receiving the racemate (150 mg), clearance of (S)-propafenone 
was significantly lower (approximately −55%) than when receiving 
the same dose of the (S)-enantiomer alone, and this resulted in 
higher plasma concentrations (Kroemer et al., 1994). The authors 
concluded that when given as a racemic mixture (R)-propafenone 
impaired the disposition of (S)-propafenone due to an enanti-
omer–enantiomer interaction along the metabolic pathway. In 
addition, propafenone undergoes extensive hepatic transforma-
tion, mainly through the CYP2D6, which activity is genetically 
determined. In another study by Kroemer et al. (1989), patients 
with the SM genotype had plasma concentrations significantly 
elevated compared with the EM group, although S/R ratios were 
similar. Clinical relevance of this stereoselective disposition in 
hERG1-related cardiotoxicity is difficult to estimate, since the 
major metabolites of propafenone also inhibit I
Kr
 (Cahill and 
Gross, 2004), and the β-blocker and Ca2+ channel antagonism of 
propafenone (Dukes and Williams, 1984) may somehow counter-
balance repolarization defects.
the PartIcular case of MethaDone as a herg1 blocker
Methadone is a synthetic analgesic drug, primarily a μ-agonist with 
pharmacological properties similar to morphine, though lacking 
some of the euphoric actions of the opium poppy alkaloid (Mattick 
et al., 2009). First synthesized in the 1930s, methadone is currently 
widely used in maintenance treatments (or MMTs) in order to 
reduce illicit opioid misuse, but also for the management of chronic 
pain, generally when other opioids are ineffective or poorly toler-
ated. Methadone is a chiral drug with an asymmetrical carbon 
(Figure 4). Although it is commonly administered as a racemic 
mixture of (R)- and (S)-methadone, the (R)-enantiomer accounts 
for most if not all of the opioid effects (Eap et al., 2002). In vitro 
competitive binding experiments (versus labeled naloxone in rat 
brain homogenates) have shown that the necessary  concentration 
with IC
50s
 of 22 and 31 nM, respectively (Jurkiewicz et al., 1996). 
The difference reported is small and potentially irrelevant, but only 
studies of hERG1 current block by the (R)-enantiomer may validate 
the possible stereoselectivity of block. The (R)-enantiomer was not 
tested because terikalant is considered to be the active enantiomer 
of RP58866. Escande et al. (1992) demonstrated that RP58866 and 
terikalant lengthened the AP in a comparable manner, while the 
(R)-isomer produced a three-fold lower effect at the same concen-
tration. Since the racemate is a 1:1 mixture of enantiomers, the pure 
active enantiomer would be expected to exert a larger effect. The 
fact that equal concentrations of racemic and pure (S)-form have 
similar effects on APD provides additional evidence supporting the 
diverse modulation by RP58866 enantiomers on various cardiac 
channels that determine the APD.
Disopyramide is another antiarrhythmic drug (class Ia) marketed 
as a racemic mixture since 1977 (Figure 4). In a study by Vanhoutte 
et al. (1991), both the (R)- and (S)-enantiomers were tested on 
guinea pig papillary muscle. At physiological K+ concentrations and 
pacing, 20 μM of (S)-disopyramide significantly increased APD by 
∼20%, while the same concentration (R)-disopyramide diminished 
APD by ∼5%. Controversy exists concerning the enantioselective 
effects on the sodium channel, the intended clinical target of dis-
opyramide, for which both the absence and increased block by the 
(R)-form have been reported (reviewed in Vanhoutte et al., 1991). 
Nevertheless, even at lower concentrations (2 μM), APD was still sig-
nificantly increased by (S)-disopyramide and not by the (R)-form, 
thus excluding it from contributing to sodium current inhibition 
(Vanhoutte et al., 1991). Importantly, this drug has been associated 
with drug-induced LQTS and TdP events (Kimura et al., 1994; 
Hirose et al., 2008). Meanwhile, disopyramide was demonstrated 
to block I
hERG1
 at clinically relevant concentrations (IC
50
 < 10 μM), 
and this action was proposed to constitute the molecular basis of 
its proarrhythmic effect (Paul et al., 2001). Investigation of the 
preferential block of I
hERG1
/I
Kr
 by disopyramide enantiomers would 
be very instructive and might lead to the reconsideration of the 
safety of the racemic administration.
Similar observations have been reported for terodiline, a drug 
used to treat incontinence. This molecule (Figure 4) was first mar-
keted in 1965 as an antianginal drug before it was re-introduced 
in the mid-1980s for urinary incontinence (reviewed in Shah, 
2002). Terodiline acts as a mixed antimuscarinic (effect of the 
(R)-terodiline) and Ca2+ channel blocker (effect of (S)-terodiline), 
and both enantiomers are considered to contribute to the beneficial 
effects on the urinary bladder (Martin et al., 2006). This antispas-
modic drug was withdrawn from the market after it was linked to 
serious tachyarrhythmias and QT interval prolongation, as well 
as to bradycardia and atrioventricular-dissociation (Hartigan-Go 
et al., 1996). Taken together, the description of the adverse effects 
likely result from excessive delay of ventricular repolarization. In 
1996, Hartigan-Go et al. studied the cardiovascular and electro-
cardiographic effects of both (R)- and (S)-terodiline on healthy 
volunteers. Interestingly, both racemic (single dose of 200 mg) and 
(R)-terodiline (100 mg) significantly increased QTc interval and 
QRS duration, while the pure (S)-enantiomer (100 mg) did not 
affect QTc values (Hartigan-Go et al., 1996). Although (S)-terodiline 
plasma concentrations were higher than those for the (R)-form, 
the authors demonstrated that the  pharmacokinetics were not 
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are at a potentially higher risk for severe cardiac arrhythmias and 
sudden death while receiving racemic methadone treatment. Since 
the (S)-enantiomer is thought to be more cardiotoxic and that 
(R)-methadone is widely accepted as the eutomer, the active enan-
tiomer for the desired effects, the authors suggested that the safety 
of the commercialized racemate toward pure (R)-methadone be 
reconsidered (Eap et al., 2007). Indeed, the administration of the 
(R)-form would decrease plasma concentrations of methadone 
by two-fold, thereby producing a safer cardiac profile, while not 
affecting the activity on the μopioid receptors. Prescription of 
(R)-methadone would also greatly diminish the clinical concern 
of CYP2B6 slow metabolizer status for cardiotoxic effects. In addi-
tion, no major changes would be expected on the other beneficial 
activities of methadone, i.e., on the N-methyl-d-aspartate receptor, 
or serotonin and norepinephrine reuptake, since in all these cases 
the (R)- is more potent than the (S)-enantiomer (reviewed in Eap 
et al., 2007). Chiral switching is the term used for the development 
and/or commercialization of single enantiomers in place of a previ-
ous racemic mixture. Reasons for marketing a pure isomer may be 
purely economic, as substitution by the single enantiomer may be a 
good way to extend patent franchise, or may result from the demon-
stration of a new safety profile, as is the case for (R)-methadone.
Eap and colleagues recently investigated in a small cohort of 39 
MMT patients the effects of the substitution of a dose of racemate 
by half-dose of (R)-methadone. They demonstrated significant 
reduction in the QTc interval values (Ansermot et al., 2010). Opioid 
adverse effects and withdrawal symptoms were either absent or of 
low intensity and remained unchanged during the study, which 
confirmed that the half-dose of (R)-methadone was therapeutically 
equivalent to the racemic mixture (Ansermot et al., 2010). These 
encouraging results, in agreement with in vitro and in vivo phar-
macogenetic data, should be confirmed by larger and prospective 
studies that can assess changes in mortality. It seems clear that as 
a preventive measure pure (R)-methadone, that is currently only 
available in Germany, should be considered for all patients (treated 
for pain or under MMT) in order to reduce the risk of cardiac 
toxic effects and sudden death. Early studies dating back to the 
1960s pointed out disadvantageous side-effects of racemic metha-
done when compared to the (R)-form, but they did not receive 
the deserved attention (reviewed in Gaertner et al., 2008). Since 
the article revealing the chiral cardiotoxicity of methadone was 
published (Eap et al., 2007), increasing number of health profes-
sionals have demanded a better assessment of the risks and pure 
(R)-methadone prescription (Gaertner et al., 2008; Lin et al., 2009; 
Wilcock and Beattie, 2009; Ansermot et al., 2010).
It is worth mentioning that the acetylated analog of metha-
done, acetylmethadol, has been implicated in several cases of severe 
arrhythmias and TdP, thus prompting its withdrawal from the 
market (Deamer et al., 2001). Acetylation of methadone creates 
an additional asymmetric center and consequently four enanti-
omers of acetylmethadol, or two pairs of diastereomers, α and 
β (Figure 4). However, only the levo-α-acetylmethadol (LAAM), 
derived from (S)-methadone, has been commercialized. Since 
the dextrorotary α-enantiomer (DAAM) derives from the active 
(R)-methadone, DAAM is expected to be more potent than LAAM 
(reviewed in Newcombe, 2006). Indeed, LAAM has proven to be 
a less potent analgesic than its diastereomer, but it appeared to be 
for the binding of the (R)-enantiomer was 10 times lower than 
that of the (S)-methadone. Similarly, a 10-fold difference of affin-
ity was found between the two enantiomers for purified μ
1
 and μ
2
 
opioid receptors. Finally, in human analgesia, (R)-methadone was 
∼50 times as potent as the (S)-form (reviewed in Eap et al., 2002). 
Despite these results, the racemate is still widely used in MMTs, 
namely because only racemic methadone is available in the inter-
national market and because of its lower cost when compared to 
the pure (R)-enantiomer (Gaertner et al., 2008).
Recent studies have demonstrated that pharmacokinetics of 
methadone, mainly the metabolism step, are highly variable owing 
to genetic and environmental influences (Eap et al., 2002; Ferrari 
et al., 2004). In humans, methadone is extensively metabolized in 
the body, predominantly by the liver and probably also the intes-
tinal cytochrome P450 isoenzymes. More precisely, CYP3A4 and 
CYP2B6 are the major isoforms involved in vivo, with CYP2D6 
contributing to a minor extent (Crettol et al., 2006). It is worth 
mentioning that the stereoselective metabolism of methadone by 
CYP2B6 has also been reported in vitro, with an estimated 1.8-fold 
preference for (S)-methadone. Crettol and co-workers confirmed 
this in vivo by assessing the influence of the CYP2B6 *6/*6 geno-
type, a slow metabolizer status representing ∼6% of Caucasians 
and Africans. These authors confirmed that CYP2B6 contributed to 
(S)-methadone metabolism and, to a lesser extent, (R)-methadone 
metabolism, with the homozygous carriers of allele *6 showing 
higher (S)- and (R,S)-methadone plasma levels (Crettol et al., 2005; 
Crettol et al., 2006).
Importantly, a disproportionate number of unexpected sudden 
deaths is seen in patients receiving methadone. Although many 
of these deaths are likely to be a result of respiratory depression, 
Torsades de Pointes is also a contributing factor (Wilcock and 
Beattie, 2009). The number of reports of cardiac events under 
methadone treatment continuously increased over the last decade 
(Valko et al., 2001; Sticherling et al., 2005; Ehret et al., 2006), thus 
raising the suspicion about block of the hERG1 channel. It was 
without surprise that methadone racemate was demonstrated to 
block I
hERG1
 in transfected HEK293 cells with an IC
50
 of ∼10 μM 
(reviewed in Eap et al., 2002).
However, given the marked differences in the pharmacokinetics 
and pharmacodynamics of the two enantiomers, neither stereose-
lectivity of hERG1 block nor metabolic implications of the CYP2B6 
*6/*6 genotype were assessed in regards to methadone cardiac 
safety until the study by Eap et al. (2007). In this study, whole-cell 
patch-clamp experiments using HEK293 cells expressing hERG1 
showed that (S)-methadone blocks I
hERG1
 3.5-fold more potently 
than (R)-methadone (IC
50s
 at 37°C: 2 and 7 μM, respectively). As 
CYP2B6 slow metabolizer status results in a reduced ability to 
metabolize (S)-methadone, ECGs, CYP2B6 genotypes, and (R)- 
and (S)-methadone plasma concentrations were obtained for a 
cohort of 179 MMT patients. Individuals identified with CYP2B6 
*6/*6 genotype showed anticipated higher plasma concentrations 
of (R,S)- and (S)-methadone, but also higher frequencies of pro-
longed and borderline QTc intervals than extensive metabolizers. 
The CYP2B6 SM status was associated with an increased risk of 
prolonged QTc (odds ratio = 4.5, P = 0.03; Eap et al., 2007). Since 
the proportion of CYP2B6 SMs in Caucasian and African popu-
lations is non-negligible (∼6%), carriers of such polymorphism 
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blockers with respect to the patient’s genetic background may be 
 possible in the future if rapid and affordable genetic screening 
tools become available. The inter-ethnic distribution of polymor-
phisms is known to be significant for drug response and should 
be taken into account when dealing with drugs that possibly affect 
cardiac repolarization.
The cavity of the hERG1 channel is large and promiscuous, 
and there might not be a therapeutic compound that is able to 
exert an “all or nothing” blocking effect. Nevertheless, there is clear 
evidence that some chiral molecules have a marked stereoselective 
effect on the hERG1 channel, and that these molecules could be 
highly informative with respect to the molecular requirements 
for drug binding and for safer enantiomeric drug development. 
Jamieson et al. (2006) reviewed the case of macrocyclic 3-ami-
nopyrrolidinone farnesyltransferase inhibitors and structural 
modifications to design out hERG1 affinity. Within this macro-
cyclic series, hERG1 binding proved to be highly sensitive to chiral 
modifications, as one (R,R) compound (Figure 4) presented high 
affinity toward hERG1 (in binding assays, IC
50 
= 0.15 μM), whereas 
its (S,R)-diastereomer did so to a lesser extent (IC
50
 = 9.1 μM). In 
addition, both presented similar potencies in the block of the phar-
macological target (Bell et al., 2002). It is likely that the chemical 
optimization of lead compounds with the introduction of chiral 
centers as well as the systematic assessment of hERG1 current 
block with all enantiomers will contribute to the reduction of the 
risk of drug-induced LQTS.
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the least toxic of all isomers in early animal studies (lower half-
maximal lethal dose). In later studies, the α-acetyl derivative of 
(S)-methadone was demonstrated to inhibit the hERG1 current 
(IC
50,LAAM
: ∼2 μM), but information about DAAM or other enan-
tiomers is lacking (Katchman et al., 2002). A study of I
hERG1
 block 
evaluating all four enantiomers of acetylmethadol could certainly 
provide useful information about the mechanisms and/or deter-
minants of the stereoselectivity toward the K+ channel.
conclusIon anD PersPectIves
About 20 years ago, Ariens and Wuis estimated that ∼57% of mar-
keted drugs were chiral and of these, ∼55% were used clinically in 
the racemic form (reviewed in Mannhold et al., 2006). For newly 
approved drugs, the tendency is toward the chiral switching or 
the development of the pure enantiomer with ∼60% of single 
enantiomers and only 5–10% of racemic mixtures accepted in the 
early 2000s (Miller, 2006; Shimazawa et al., 2008). This observa-
tion reveals that researchers are increasingly aware of the com-
plex effects of enantiomers. Although the pharmacokinetics and 
PD of chiral compounds are routinely investigated, thus far the 
pharmacogenetic risks and the stereoselective bock of the hERG1 
channel have only been scarcely studied. In this review, we pre-
sented a non-exhaustive list of the compounds displaying chiral 
toxicity that is most likely related to hERG1-blocking properties. 
The particular case of methadone illustrates the need to consider 
the overall stereoselective effect of a chiral drug while taking into 
account any known pharmacogenetic information. Even though 
methadone is not a high-affinity blocker of hERG1 (IC
50s
 in the 
μM range), and that a 3.5-fold difference between enantiomers 
might not be clinically relevant, the difference in hERG1 inhibition 
is accompanied by additional stereoselective PK and PD proper-
ties influencing (S)-methadone toxicity. Careful use of hERG1 
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